IsoRay (ISR) Brain Cancer Results 'Impressive' - Maxim Group

Maxim Group analyst Jason Kolbert reiterated a Buy rating and $5 price target on IsoRay, Inc. (NYSE: ISR) following 'impressive' Barrow study brain cancer results.

Kolbert highlighted:

• The Barrow study reported on 27 patients who had a variety of deadly brain cancers, including high grade gliomas, high grade meningiomas, and brain metastases. The patients had received an average of 2 and as many as 4 extensive earlier treatments that had failed, resulting in a recurrence of their cancers in the same locations where treatment had previously been applied
• Oncologists at the Barrow Neurological Institute employed a technique developed by GammaTile, LLC that provides an intensive dose of Cesium-131-based radiation in tandem with surgical removal of these malignant growths. Following surgical removal of the tumor tissue, Cesium-131 was delivered to the targeted brain tissue using a modular, pre-commercial biocompatible carrier system that provided custom-tailored implants for each patient.
• The company is taking the steps with studies like this one to build awareness around Cs-131 with leading medical institutions. The company is also hiring nine additional field reps this month to be located throughout the US. With Cs-131 approved for most solid tumors, broader adoption is key to market penetration. Management is seeing interest building in the treatment of brain cancers (meningiomas, brain metastases, and glioblastomas), lung cancer (NSCLC), gynecological cancer, prostate cancer, head and neck cancer, and liquid Cesium-131 in the GliaSite Radiation Therapy System, used to treat brain cancers.

For an analyst ratings summary and ratings history on IsoRay, Inc. click here. For more ratings news on IsoRay, Inc. click here.

Shares of IsoRay, Inc. closed at $1.62 yesterday.

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• New Street Research Upgrades Micron Technology (MU) to Buy
• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'